Dumbo is contradicting SeagalRule of thumb for all companies; spend if you must, spend money when you think it will generate a return.
Don't spend and cut when a project goes wrong....
4601 GBM trial and 232 trial are proceeding extremely well... Thallion is spending cash on cutting edge clinical software management
This lobster statement by Dumbo is in total contradiction with what CEO Seagal said in the last two Conference calls. In these two calls Seagal said clearly that the point of decision to continue or not would be half way (18-22 patients). It is the minimal number of patients for the doctors to see if there is a positive trend or not. He clearly stated that without a positive trend the trial would be stopped. But we are not there yet. So Dumbo is clearly contradicting Seagal. But Seagal is not thinking like a lobster. This is probably why he decided in advance to sell the company tax losses in order to get more money. The best scenario in my opinion is non spectacular interim data just good enough to continue the trial. So no increase in stock price, no partnership and no takeover. The worst case scenario is no positive trend in the interim results and stoppage of the trial. Maybe another trial with another indication.
Like it or not. The tax losses selling and the departure of Falardeau are two bad signs about what is going on with GBM trial. If it is going bad with the GBM trial, it would explain why Falardeau left and why they decided at the same time to do the tax losses selling. More money ahead of a bad news.